Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Boehringer Ingelheim Venture Fund (BIVF)

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF's focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, in regenerative medicine or gene therapy. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy. BIVF takes an active role with its portfolio companies - delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has €200 million under management and currently supervises a portfolio of more than 20 companies. *

 

Period Start 2010-03-01 established
Products Industry venture capital
  Industry 2 pharmaceutical
Persons Person Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)
  Person 2 Kostka, Marcus (Boehringer 201410 Director at Boehringer Ingelheim Venture Fund)
     
Region Region Ingelheim
  Country Germany
  Street 173 Binger Str.
  City 55216 Ingelheim
  Tel +49-6132-77-8740
    Address record changed: 2010-09-18
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 200,000,000 (capital under management 2018-01-04)
     
    * Document for �About Section�: Rewind Therapeutics. (1/4/18). "Press Release: Rewind Therapeutics Secures 15.2m Euro to Develop Novel Remyelination Therapies". Leuven.
     
   
Record changed: 2018-12-04

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for Boehringer Ingelheim Venture Fund (BIVF)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top